CAPNIA is a private company developing novel therapeutic products using its proprietary medical gas delivery system. We are targeting a number of chronic diseases treatable with topical application of well understood, safe and effective gas compounds. Our first product is entering Phase IIb clinical trials for the treatment of acute migraines and related symptoms. 28 million Americans and over 240 million people worldwide suffer from this debilitating condition.
|04/24/08||Series C||16.3M||Rocket Internet, Kohlberg Ventures, SBA Communications, HSBC Group, Morgan Stanley Investment Management, Lazard Asset Management, Ofer Hi-Tech Holdings, Klein Venture Partners||Unknown|